FULCRUM THERAPEUTICS, INC. Comprehensive Income
FULCRUM THERAPEUTICS, INC. (FULC) reported Comprehensive Income of -$26.23 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$26.23M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$19.58M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$20.40M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$19.44M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$96.67M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$110.27M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$81.24M.
- FULCRUM THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$70.82M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.23M S-4 · filed 2026-09-02 | -$45.81M S-4 · filed 2026-09-02 | -$66.21M derived: sum of 3 quarters · filed 2026-09-02 | -$85.65M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | -$19.58M 10-Q · filed 2026-04-27 | -$39.98M derived: sum of 2 quarters · filed 2026-09-02 | -$59.41M derived: sum of 3 quarters · filed 2026-09-02 | -$76.70M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | -$20.40M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | -$39.84M derived: sum of 2 quarters · filed 2026-09-02 | -$57.12M derived: sum of 3 quarters · filed 2026-09-02 | -$74.84M S-4 · filed 2026-09-02 |
| 2025-09-30 | -$19.44M 10-Q · filed 2025-10-29 | -$36.72M derived: sum of 2 quarters · filed 2026-09-02 | -$54.44M 10-Q · filed 2025-10-29 | -$71.25M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | -$17.28M S-4 · filed 2026-09-02 | -$35.00M S-4 · filed 2026-09-02 | -$51.82M derived: sum of 3 quarters · filed 2026-09-02 | -$72.77M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | -$17.71M 10-Q · filed 2026-04-27 | -$34.53M derived: sum of 2 quarters · filed 2026-09-02 | -$55.48M derived: sum of 3 quarters · filed 2026-09-02 | -$6.00K derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | -$16.82M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | -$37.77M derived: sum of 2 quarters · filed 2026-09-02 | $17.71M derived: sum of 3 quarters · filed 2026-09-02 | -$9.46M S-4 · filed 2026-09-02 |
| 2024-09-30 | -$20.95M 10-Q · filed 2025-10-29 | $34.53M derived: sum of 2 quarters · filed 2025-10-29 | $7.36M 10-Q · filed 2025-10-29 | -$16.65M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $55.48M 10-Q · filed 2025-07-29 | $28.31M 10-Q · filed 2025-07-29 | $4.30M derived: sum of 3 quarters · filed 2025-07-29 | -$19.40M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | -$27.17M 10-Q · filed 2025-05-01 | -$51.17M derived: sum of 2 quarters · filed 2025-05-01 | -$74.88M derived: sum of 3 quarters · filed 2025-05-01 | -$99.21M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$24.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$47.71M derived: sum of 2 quarters · filed 2025-02-25 | -$72.04M derived: sum of 3 quarters · filed 2025-02-25 | -$96.67M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$23.70M 10-Q · filed 2024-11-13 | -$48.03M derived: sum of 2 quarters · filed 2024-11-13 | -$72.67M 10-Q · filed 2024-11-13 | -$98.68M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$24.33M 10-Q · filed 2024-07-31 | -$48.97M 10-Q · filed 2024-07-31 | -$74.98M derived: sum of 3 quarters · filed 2024-07-31 | -$98.57M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | -$24.63M 10-Q · filed 2024-05-13 | -$50.64M derived: sum of 2 quarters · filed 2024-05-13 | -$74.23M derived: sum of 3 quarters · filed 2024-05-13 | -$108.28M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$26.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$49.60M derived: sum of 2 quarters · filed 2024-02-27 | -$83.65M derived: sum of 3 quarters · filed 2024-02-27 | -$110.27M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$23.59M 10-Q · filed 2023-11-07 | -$57.64M derived: sum of 2 quarters · filed 2023-11-07 | -$84.26M 10-Q · filed 2023-11-07 | -$108.05M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$34.05M 10-Q · filed 2023-08-03 | -$60.67M 10-Q · filed 2023-08-03 | -$84.46M derived: sum of 3 quarters · filed 2023-08-03 | -$105.26M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$26.62M 10-Q · filed 2023-05-15 | -$50.41M derived: sum of 2 quarters · filed 2023-06-26 | -$71.21M derived: sum of 3 quarters · filed 2023-06-26 | -$90.86M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | -$23.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$44.59M derived: sum of 2 quarters · filed 2023-06-26 | -$64.24M derived: sum of 3 quarters · filed 2023-06-26 | -$81.24M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | -$20.79M 10-Q · filed 2022-11-08 | -$40.45M derived: sum of 2 quarters · filed 2022-11-08 | -$57.45M 10-Q · filed 2022-11-08 | -$75.20M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | -$19.65M 10-Q · filed 2022-08-11 | -$36.65M 10-Q · filed 2022-08-11 | -$54.41M derived: sum of 3 quarters · filed 2023-06-26 | -$73.42M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | -$17.00M 10-Q · filed 2022-05-09 | -$34.75M derived: sum of 2 quarters · filed 2023-06-26 | -$53.77M derived: sum of 3 quarters · filed 2023-06-26 | -$69.32M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | -$17.75M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$36.77M derived: sum of 2 quarters · filed 2023-06-26 | -$52.32M derived: sum of 3 quarters · filed 2023-06-26 | -$70.82M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | -$19.01M 10-Q · filed 2021-11-04 | -$34.56M derived: sum of 2 quarters · filed 2021-11-04 | -$53.07M 10-Q · filed 2021-11-04 | -$69.19M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | -$15.55M 10-Q · filed 2021-08-10 | -$34.06M 10-Q · filed 2021-08-10 | -$50.18M derived: sum of 3 quarters · filed 2023-06-23 | -$66.72M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | -$18.50M 10-Q · filed 2021-05-06 | -$34.63M derived: sum of 2 quarters · filed 2023-06-23 | -$51.17M derived: sum of 3 quarters · filed 2023-06-23 | -$64.34M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | -$16.12M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | -$32.66M derived: sum of 2 quarters · filed 2023-06-23 | -$45.83M derived: sum of 3 quarters · filed 2023-06-23 | -$82.68M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | -$16.54M 10-Q · filed 2020-11-10 | -$29.71M derived: sum of 2 quarters · filed 2020-11-10 | -$66.55M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$13.17M 10-Q · filed 2020-08-11 | -$50.01M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$36.84M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |